Shares of STAAR Surgical Company (NASDAQ:STAA – Get Free Report) have been given a consensus rating of “Hold” by the thirteen analysts that are presently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, seven have given a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $28.40.
Several brokerages recently weighed in on STAA. Zacks Research upgraded STAAR Surgical from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 4th. William Blair set a $33.00 price objective on STAAR Surgical in a research note on Thursday, August 13th. Mizuho lifted their target price on STAAR Surgical from $22.00 to $27.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. Wall Street Zen downgraded STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $28.00 target price on shares of STAAR Surgical in a report on Thursday, August 13th.
View Our Latest Stock Analysis on STAA
Hedge Funds Weigh In On STAAR Surgical
STAAR Surgical Price Performance
Shares of NASDAQ:STAA opened at $22.59 on Friday. STAAR Surgical has a 1 year low of $15.59 and a 1 year high of $35.87. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of 322.76 and a beta of 1.26. The company’s 50 day simple moving average is $25.53 and its 200 day simple moving average is $24.58.
STAAR Surgical (NASDAQ:STAA – Get Free Report) last released its earnings results on Wednesday, August 12th. The medical instruments supplier reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.17. STAAR Surgical had a return on equity of 9.05% and a net margin of 1.13%.The firm had revenue of $93.53 million during the quarter, compared to analysts’ expectations of $90.60 million. During the same period in the prior year, the company earned ($0.34) earnings per share. The company’s quarterly revenue was up 111.1% on a year-over-year basis. As a group, analysts anticipate that STAAR Surgical will post 0.39 EPS for the current fiscal year.
About STAAR Surgical
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.
See Also
- Five stocks we like better than STAAR Surgical
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
